Deborah A. Hall
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Deborah A. Hall has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Maureen A. Leehey
Department of Neurology, University of Colorado at Denver and Health Sciences Center, Denver, CO, United States
2 shared publicationsAlejandro A. Espinoza Orías
Motion Analysis Laboratory, Department of Orthopedic Surgery, Rush University Medical Center, Chicago, IL 60612, United States
1 shared publication- Annie Laurie Shroyer
Northport VA Medical Center Research and Development Office (151), 79 Middleville Rd, Bldg 62/Rm 125, Northport, NY 11768
1 shared publication C. M. Filley
1 shared publicationCathlin D. Rice
Department of Clinical Genetics and Metabolism, The Children's Hospital, Denver, Colorado, USA
1 shared publicationE. Steinbart
1 shared publication
Latest Publications
- 1 February 2014
- Published by Elsevier in Gait & Posture
- Vol. 39 (2) , 827-830
Implementation of a markerless motion analysis method to quantify hyperkinesis in males with fragile X syndrome
- 1 February 2014
- Published by Elsevier in Gait & Posture
- Vol. 39 (2) , 827-830
Implementation of a markerless motion analysis method to quantify hyperkinesis in males with fragile X syndrome
- 1 February 2009
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 15 (2) , 156-159
Parkinsonism in FMR1 premutation carriers may be indistinguishable from Parkinson disease
- 1 February 2009
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 15 (2) , 156-159
Parkinsonism in FMR1 premutation carriers may be indistinguishable from Parkinson disease
- 1 May 2007
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 55 (4) , 181-186
Clinical Science Training at the University of Colorado: A Measurement of Trainee Satisfaction
Background: Clinical science (CLSC) research education differs from basic science education in that many CLSC programs have an added goal of creating successful academicians. CLSC programs have expanded curricula that include teaching career development techniques, such as manuscript and grant writing, and helping young investigators establish successful mentor-mentee relationships. Methods: A group of K30 CLSC training program students coordinated a pilot survey to determine if the CLSC training programs at the University of Colorado were meeting the needs of the participants in both didactic courses and in other aspects of academic medicine, including research. The small group survey was conducted as part of a clinical outcomes assessment course. Opportunities for improvement in the CLSC training programs were explored based on the results. Results: Of 117 CLSC training program participants surveyed, 56% responded. Overall, there was a positive improvement found for the didactic CLSC research constructs. Participants also reported success in manuscript publication and grant writing applications. The CLSC program, however, was not successful in coordinating faculty mentor support for student research projects for 78% of respondents. Once a mentoring relationship was established, students were satisfied with the mentoring they received. Conclusion: In general, CLSC trainees were satisfied that the K30 clinical research curriculum was meeting their needs. Many of the trainees were successful in developing academic skills during the program. Establishing a mentor relationship was the missing ingredient within the K30 CLSC training program. This may be an important component that should be considered when developing programs to create the next generation of clinician-scientists.
- 1 May 2007
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 55 (4) , 181-186
Clinical Science Training at the University of Colorado: A Measurement of Trainee Satisfaction
Background: Clinical science (CLSC) research education differs from basic science education in that many CLSC programs have an added goal of creating successful academicians. CLSC programs have expanded curricula that include teaching career development techniques, such as manuscript and grant writing, and helping young investigators establish successful mentor-mentee relationships. Methods: A group of K30 CLSC training program students coordinated a pilot survey to determine if the CLSC training programs at the University of Colorado were meeting the needs of the participants in both didactic courses and in other aspects of academic medicine, including research. The small group survey was conducted as part of a clinical outcomes assessment course. Opportunities for improvement in the CLSC training programs were explored based on the results. Results: Of 117 CLSC training program participants surveyed, 56% responded. Overall, there was a positive improvement found for the didactic CLSC research constructs. Participants also reported success in manuscript publication and grant writing applications. The CLSC program, however, was not successful in coordinating faculty mentor support for student research projects for 78% of respondents. Once a mentoring relationship was established, students were satisfied with the mentoring they received. Conclusion: In general, CLSC trainees were satisfied that the K30 clinical research curriculum was meeting their needs. Many of the trainees were successful in developing academic skills during the program. Establishing a mentor relationship was the missing ingredient within the K30 CLSC training program. This may be an important component that should be considered when developing programs to create the next generation of clinician-scientists.
- 15 April 2007
- Published by Wiley in Movement Disorders
- Vol. 22 (5) , 708-710
Paroxysmal nonkinesigenic dystonia and celiac disease
Celiac disease has been associated with ataxia and other neurological signs but has not been associated with paroxysmal nonkinesigenic dyskinesias (PNKD) to date. We present a child with biopsy‐proven celiac disease and a movement disorder resembling PNKD since the age of 6 months. She had complete resolution of her neurological symptoms with introduction of a gluten‐free diet. Because a susceptibility locus for celiac disease has been reported on 2q33 and studies in PNKD show linkage to 2q, this report suggests further genetic investigations around this locus may be useful. We also review the literature regarding the genetic susceptibility to PNKD and celiac disease. © 2007 Movement Disorder Society
- 15 April 2007
- Published by Wiley in Movement Disorders
- Vol. 22 (5) , 708-710
Paroxysmal nonkinesigenic dystonia and celiac disease
Celiac disease has been associated with ataxia and other neurological signs but has not been associated with paroxysmal nonkinesigenic dyskinesias (PNKD) to date. We present a child with biopsy‐proven celiac disease and a movement disorder resembling PNKD since the age of 6 months. She had complete resolution of her neurological symptoms with introduction of a gluten‐free diet. Because a susceptibility locus for celiac disease has been reported on 2q33 and studies in PNKD show linkage to 2q, this report suggests further genetic investigations around this locus may be useful. We also review the literature regarding the genetic susceptibility to PNKD and celiac disease. © 2007 Movement Disorder Society
- 1 September 2006
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 21 (9) , 795-798
Maternal Risk Factors for Term Neonatal Seizures: Population-Based Study in Colorado, 1989—2003
Neonatal seizures in term infants are rare but have important potential implications for brain development. Risk factors for neonatal seizures in term infants have been less well defined than those among preterm infants. To evaluate the relationship between maternal risk factors and neonatal seizures in the first 72 hours of life in term infants, a case-control study using the Colorado Birth Certificate Registry was conducted. Term neonates in all hospitals in Colorado with and without seizures in the first 72 hours were studied. After adjusting for vaginal delivery in the setting of herpes infection and post-term delivery, preexisting diabetes in the mother (odds ratio 4.30, 95% confidence interval 1.64—11.27, P < .01) and fetal distress (odds ratio 5.88, 95% confidence interval 4.60—7.13, P < .0001) were independent risk factors for neonatal seizures in term infants. These findings are confirmatory of previous reports that maternal preexisting diabetes and fetal distress increase the risk of neonatal seizure in term infants. Although we cannot establish the pathophysiology of neonatal seizures from this analysis, hypoxic-ischemic brain injury and hypoglycemia in infants of diabetic mothers are known causes of neonatal seizures that can be represented in this analysis by fetal distress and maternal preexisting diabetes, respectively. Maternal diabetic vasculopathy can also be a contributing factor. (J Child Neurol 2006;21:795—798; DOI 10.2310/7010.2006.00189).
- 1 September 2006
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 21 (9) , 795-798
Maternal Risk Factors for Term Neonatal Seizures: Population-Based Study in Colorado, 1989—2003
Neonatal seizures in term infants are rare but have important potential implications for brain development. Risk factors for neonatal seizures in term infants have been less well defined than those among preterm infants. To evaluate the relationship between maternal risk factors and neonatal seizures in the first 72 hours of life in term infants, a case-control study using the Colorado Birth Certificate Registry was conducted. Term neonates in all hospitals in Colorado with and without seizures in the first 72 hours were studied. After adjusting for vaginal delivery in the setting of herpes infection and post-term delivery, preexisting diabetes in the mother (odds ratio 4.30, 95% confidence interval 1.64—11.27, P < .01) and fetal distress (odds ratio 5.88, 95% confidence interval 4.60—7.13, P < .0001) were independent risk factors for neonatal seizures in term infants. These findings are confirmatory of previous reports that maternal preexisting diabetes and fetal distress increase the risk of neonatal seizure in term infants. Although we cannot establish the pathophysiology of neonatal seizures from this analysis, hypoxic-ischemic brain injury and hypoglycemia in infants of diabetic mothers are known causes of neonatal seizures that can be represented in this analysis by fetal distress and maternal preexisting diabetes, respectively. Maternal diabetic vasculopathy can also be a contributing factor. (J Child Neurol 2006;21:795—798; DOI 10.2310/7010.2006.00189).
- 13 June 2006
- Published by Wiley in Movement Disorders
- Vol. 21 (10) , 1741-1744
Symptomatic treatment in the fragile X–associated tremor/ataxia syndrome
There is no established treatment for the neurological features of the recently discovered fragile X–associated tremor/ataxia syndrome (FXTAS). Fifty‐six patients with FXTAS completed a questionnaire to determine whether any medications had been effective for neurological symptoms. Of 11 subjects with definite FXTAS, 8 (70%) were on medications for their neurological symptoms, whereas most subjects with possible or probable FXTAS, 31 (70%) of 45 subjects, were not on medications. Although no therapy was uniformly effective for intention tremor, ataxia, Parkinsonism, memory loss, or anxiety, some subjects with intention tremor or Parkinsonism reported improvement with medications frequently used in other movement disorders. Overall, all 22 subjects on medications reported improvement in one or more symptoms. Lack of insight, recall bias, and cognitive impairment may have resulted in an underestimation of the beneficial effect of medical therapy. This study suggests that patients with FXTAS can derive improvement from medication treatment for some of their symptoms. © 2006 Movement Disorder Society
- 13 June 2006
- Published by Wiley in Movement Disorders
- Vol. 21 (10) , 1741-1744
Symptomatic treatment in the fragile X–associated tremor/ataxia syndrome
There is no established treatment for the neurological features of the recently discovered fragile X–associated tremor/ataxia syndrome (FXTAS). Fifty‐six patients with FXTAS completed a questionnaire to determine whether any medications had been effective for neurological symptoms. Of 11 subjects with definite FXTAS, 8 (70%) were on medications for their neurological symptoms, whereas most subjects with possible or probable FXTAS, 31 (70%) of 45 subjects, were not on medications. Although no therapy was uniformly effective for intention tremor, ataxia, Parkinsonism, memory loss, or anxiety, some subjects with intention tremor or Parkinsonism reported improvement with medications frequently used in other movement disorders. Overall, all 22 subjects on medications reported improvement in one or more symptoms. Lack of insight, recall bias, and cognitive impairment may have resulted in an underestimation of the beneficial effect of medical therapy. This study suggests that patients with FXTAS can derive improvement from medication treatment for some of their symptoms. © 2006 Movement Disorder Society
- 1 April 2006
- Published by S. Karger AG in Neuroepidemiology
- Vol. 26 (3) , 151-155
Prevalence of FMR1 Repeat Expansions in Movement Disorders
We reviewed prevalence rates of fragile X mental retardation gene (FMR1) repeat expansions in movement disorder populations. Inclusion criteria included published epidemiological studies from systematic searches of Medline, Pubmed, Cochrane Databases and Web Science. Thirteen cross-sectional studies were carried out between 2003 and 2005. Subjects with ataxia showed higher than expected rates while those with essential tremor and parkinsonism showed lower rates. The heterogeneous design of the studies, inclusion criteria and mean age of subjects may have led to underestimation of FMR1 repeat expansion prevalence rates.
- 1 April 2006
- Published by S. Karger AG in Neuroepidemiology
- Vol. 26 (3) , 151-155
Prevalence of FMR1 Repeat Expansions in Movement Disorders
We reviewed prevalence rates of fragile X mental retardation gene (FMR1) repeat expansions in movement disorder populations. Inclusion criteria included published epidemiological studies from systematic searches of Medline, Pubmed, Cochrane Databases and Web Science. Thirteen cross-sectional studies were carried out between 2003 and 2005. Subjects with ataxia showed higher than expected rates while those with essential tremor and parkinsonism showed lower rates. The heterogeneous design of the studies, inclusion criteria and mean age of subjects may have led to underestimation of FMR1 repeat expansion prevalence rates.
- 12 April 2005
- Published by Wolters Kluwer Health in Neurology
- Vol. 64 (7) , 1304-1306
PRNP H187R mutation associated with neuropsychiatric disorders in childhood and dementia
Described is a large family with an autosomal dominant dementia associated with an H187R mutation in the prion protein gene (PRNP). Clinical features include neuropsychiatric disturbances in childhood and adolescence, dementia in young adulthood with frontotemporal manifestations, and long disease duration. Neuropathology revealed atrophy and mild gliosis, whereas prion protein analysis revealed an abnormal conformer with unusual sensitivity to protease digestion. Mutations in PRNP may cause neuropsychiatric disorders that predate dementia by many years.
- 12 April 2005
- Published by Wolters Kluwer Health in Neurology
- Vol. 64 (7) , 1304-1306
PRNP H187R mutation associated with neuropsychiatric disorders in childhood and dementia
Described is a large family with an autosomal dominant dementia associated with an H187R mutation in the prion protein gene (PRNP). Clinical features include neuropsychiatric disturbances in childhood and adolescence, dementia in young adulthood with frontotemporal manifestations, and long disease duration. Neuropathology revealed atrophy and mild gliosis, whereas prion protein analysis revealed an abnormal conformer with unusual sensitivity to protease digestion. Mutations in PRNP may cause neuropsychiatric disorders that predate dementia by many years.